A telehealth intake connects you with a licensed provider who decides whether a prescription is appropriate.
You complete a health questionnaire; a licensed provider reviews it and decides whether treatment is clinically appropriate. If prescribed, a pharmacy fills it and ships to you. A legitimate flow requires a real evaluation — a site that sells medication without a prescription or evaluation is a red flag.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.